title: Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.
abstract: There is currently no licensed vaccine for noroviruses, and development is hindered, in part, by an incomplete understanding of the host adaptive immune response to these highly heterogeneous viruses and rapid GII.4 norovirus molecular evolution. Emergence of a new predominant GII.4 norovirus strain occurs every 2 to 4 years. To address the problem of GII.4 antigenic variation, we tested the hypothesis that chimeric virus-like particle (VLP)-based vaccine platforms, which incorporate antigenic determinants from multiple strains into a single genetic background, will elicit a broader immune response against contemporary and emergent strains. Here, we compare the immune response generated by chimeric VLPs to that of parental strains and a multivalent VLP cocktail. Results demonstrate that chimeric VLPs induce a more broadly cross-blocking immune response than single parental VLPs and a similar response to a multivalent GII.4 VLP cocktail. Furthermore, we show that incorporating epitope site A alone from one strain into the background of another is sufficient to induce a blockade response against the strain donating epitope site A. This suggests a mechanism by which population-wide surveillance of mutations in a single epitope could be used to evaluate antigenic changes in order to identify potential emergent strains and quickly reformulate vaccines against future epidemic strains as they emerge in human populations.
  
  
  OBJECTIVE
  Noroviruses are gastrointestinal pathogens that infect an estimated 21 million people per year in the United States alone. GII.4 noroviruses account for >70% of all outbreaks, making them the most clinically important genotype. GII.4 noroviruses undergo a pattern of epochal evolution, resulting in the emergence of new strains with altered antigenicity over time, complicating vaccine design. This work is relevant to norovirus vaccine design as it demonstrates the potential for development of a chimeric VLP-based vaccine platform that may broaden the protective response against multiple GII.4 strains and proposes a potential reformulation strategy to control newly emergent strains in the human population.
authors.affiliation: Department of Microbiology and Immunology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
authors.forename: Kari
authors.initials: K
authors.lastname: Debbink
authors.affiliation: Department of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
authors.forename: Lisa C
authors.initials: LC
authors.lastname: Lindesmith
authors.affiliation: Department of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
authors.forename: Eric F
authors.initials: EF
authors.lastname: Donaldson
authors.affiliation: Department of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA.
authors.forename: Jesica
authors.initials: J
authors.lastname: Swanstrom
authors.affiliation: Department of Microbiology and Immunology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA Department of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, USA rbaric@sph.unc.edu.
authors.forename: Ralph S
authors.initials: RS
authors.lastname: Baric
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D000940:Antigenic Variation / Q000276:immunology*; D017250:Caliciviridae Infections / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D000939:Epitopes / Q000235:genetics / Q000276:immunology*; D006801:Humans; D016867:Immunocompromised Host / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D029322:Norovirus / Q000276:immunology* / Q000302:isolation & purification; D011487:Protein Conformation; D011993:Recombinant Fusion Proteins / Q000276:immunology*; D058425:Vaccines, Virus-Like Particle / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D000914:Antibodies, Viral; D036022:Capsid Proteins; D000939:Epitopes; D011993:Recombinant Fusion Proteins; D058425:Vaccines, Virus-Like Particle
references.citation: Gastroenterology. 2002 Jun;122(7):1967-77
references.pmid: 12055602
references.citation: J Virol. 2012 Jan;86(2):1214-26
references.pmid: 22090110
references.citation: Science. 1999 Oct 8;286(5438):287-90
references.pmid: 10514371
references.citation: Euro Surveill. 2013 Jan 03;18(1):8-9
references.pmid: 23305715
references.citation: J Infect Dis. 2002 Jul 1;186(1):1-7
references.pmid: 12089655
references.citation: Emerg Infect Dis. 2011 Jan;17(1):7-15
references.pmid: 21192848
references.citation: J Virol. 2011 Sep;85(17):8656-66
references.pmid: 21715504
references.citation: Vaccine. 2012 Nov 19;30(49):7097-104
references.pmid: 23026689
references.citation: Arch Virol. 2013 Oct;158(10):2059-68
references.pmid: 23615870
references.citation: J Virol. 2011 Sep;85(17):8635-45
references.pmid: 21715503
references.citation: Emerg Infect Dis. 2008 Aug;14(8):1224-31
references.pmid: 18680645
references.citation: J Virol. 2007 Jun;81(11):5949-57
references.pmid: 17392366
references.citation: N Engl J Med. 1977 Jul 14;297(2):86-9
references.pmid: 405590
references.citation: PLoS Pathog. 2012;8(5):e1002705
references.pmid: 22615565
references.citation: J Virol. 2010 Feb;84(4):1800-15
references.pmid: 20007270
references.citation: J Biol Stand. 1988 Oct;16(4):269-73
references.pmid: 3198657
references.citation: Vaccine. 2002 May 15;20 Suppl 2:S5-14
references.pmid: 12110248
references.citation: J Infect Dis. 1999 Dec;180(6):2018-22
references.pmid: 10558961
references.citation: J Virol. 2011 Jan;85(1):231-42
references.pmid: 20980508
references.citation: N Engl J Med. 2011 Dec 8;365(23):2178-87
references.pmid: 22150036
references.citation: Nat Med. 2003 May;9(5):548-53
references.pmid: 12692541
references.citation: Vaccine. 2008 Aug 5;26(33):4267-75
references.pmid: 18582997
references.citation: J Clin Microbiol. 2014 Jan;52(1):147-55
references.pmid: 24172151
references.citation: Nature. 2014 Mar 13;507(7491):201-6
references.pmid: 24499818
references.citation: J Virol. 2013 Mar;87(5):2803-13
references.pmid: 23269783
references.citation: J Virol. 2002 Jan;76(2):730-42
references.pmid: 11752163
references.citation: J Gen Virol. 2005 Oct;86(Pt 10):2799-2806
references.pmid: 16186235
references.citation: J Med Virol. 2008 Aug;80(8):1468-76
references.pmid: 18551613
references.citation: J Infect Dis. 2014 Apr 1;209(7):1016-22
references.pmid: 24253285
references.citation: J Virol. 2014 Jan;88(2):829-37
references.pmid: 24173225
references.citation: PLoS Pathog. 2010 May 06;6(5):e1000884
references.pmid: 20463813
references.citation: Am J Trop Med Hyg. 2009 Feb;80(2):302-11
references.pmid: 19190230
references.citation: J Virol. 2012 Jan;86(2):873-83
references.pmid: 22090098
references.citation: Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9175-80
references.pmid: 18599458
references.citation: Virology. 2006 Mar 15;346(2):312-23
references.pmid: 16343580
references.citation: J Appl Microbiol. 2010 Nov;109(5):1753-62
references.pmid: 21040268
references.citation: Emerg Infect Dis. 2011 Aug;17(8):1389-95
references.pmid: 21801614
references.citation: J Virol. 2009 Apr;83(7):3212-27
references.pmid: 19176631
references.citation: J Infect Dis. 2013 Dec 1;208(11):1877-87
references.pmid: 23908476
references.citation: Vaccine. 2010 Apr 26;28(19):3479-87
references.pmid: 20211219
references.citation: J Med Virol. 2000 Jan;60(1):97-101
references.pmid: 10568770
references.citation: Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1939-44
references.pmid: 24385585
references.citation: Emerg Infect Dis. 2013 Aug;19(8):1260-7
references.pmid: 23876612
references.citation: J Virol. 2011 May;85(9):4057-70
references.pmid: 21345963
references.citation: J Infect Dis. 2010 Oct 15;202(8):1212-8
references.pmid: 20815703
references.citation: Vaccine. 2006 Jun 12;24(24):5220-34
references.pmid: 16650512
references.citation: Proc Natl Acad Sci U S A. 2006 May 23;103(21):8048-53
references.pmid: 16702551
references.citation: PLoS Med. 2008 Feb;5(2):e31
references.pmid: 18271619
references.citation: J Virol. 2002 Mar;76(6):3023-30
references.pmid: 11861868
references.citation: Vaccine. 2012 May 21;30(24):3580-6
references.pmid: 22469864